Clinical Trial Results
Showing:
All studies
[change]
Condition: Breast Cancer
Location: Charlottesville, Virginia
23 trials found
New Search
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
RECRUITING
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RECRUITING
Pan Tumor Rollover Study
RECRUITING
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
RECRUITING
Contrast-enhanced Spectral Mammography (CESM) Breast Cancer Screening
RECRUITING
A Study of NX-1607 in Adults With Advanced Malignancies
RECRUITING
Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer
RECRUITING
Pre-Operative Window of ET to Inform RT Decisions (POWER II)
RECRUITING
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
RECRUITING
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
RECRUITING
HER2 FPBMC in Patients With Metastatic Breast and Prostate Cancer (AM006)
RECRUITING
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
RECRUITING
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
RECRUITING
Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts
RECRUITING
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
RECRUITING
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
RECRUITING
FOG-001 in Locally Advanced or Metastatic Solid Tumors
RECRUITING
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
RECRUITING
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
RECRUITING
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RECRUITING
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
RECRUITING
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
RECRUITING
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
RECRUITING